Brief: Poxel: Phase 2 For PXL065 In Nash Achieved Primary Efficacy Endpoint For Liver Fat Content Reduction For All Doses

Poxel SA

12/10/2022 06:32

Oct 12 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL TO PRESENT DESTINY-1 PHASE 2 RESULTS FOR PXL065 IN
NASH AT
AASLD THE LIVER MEETING® 2022
    * PHASE 2 FOR PXL065 IN NASH ACHIEVED PRIMARY EFFICACY
ENDPOINT
FOR LIVER FAT CONTENT REDUCTION FOR ALL DOSES AND SHOWED STRONG
IMPROVEMENT IN FIBROSIS WITHOUT WORSENING OF NASH

Source text for Eikon:  ID:nBw2C12q0a 
Further company coverage:  POXEL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))